Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration

Biomaterials

Volumn 106, Issue , 2016, Pages 205-216

  Shen, Xiaofeng ^a   Zhang, Yanxia ^b   Gu, Yong ^a   Xu, Yun ^a   Liu, Yong ^a   Li, Bin ^a,b   Chen, Liang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Bone morphogenetic protein 2; Bone regeneration; Controlled release; Nano hydroxyapatite; Silk fibroin; Stromal cell derived factor 1

Indexed keywords

BONE; CELL CULTURE; CELL ENGINEERING; CELLS; CYTOLOGY; MICROSPHERES; NANOCOMPOSITES; PROTEINS; STEM CELLS; TISSUE; TISSUE ENGINEERING;

BONE MORPHOGENETIC PROTEIN-2; BONE REGENERATION; CONTROLLED RELEASE; NANO-HYDROXYAPATITE; SILK FIBROIN; STROMAL CELLS;

SCAFFOLDS (BIOLOGY);

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; HYDROXYAPATITE; LUCIFERIN; OSTEOCALCIN; OSTEOPONTIN; SILK FIBROIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RUNX2; BMP2 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; FIBROIN; NANOPARTICLE;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE REGENERATION; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENCAPSULATION; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG IMPLANT; MESENCHYMAL STROMA CELL; OSTEOBLAST; PHYSIOLOGY; SKULL FRACTURE; SPRAGUE DAWLEY RAT; TISSUE SCAFFOLD;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CHEMOKINE CXCL12; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DURAPATITE; FIBROINS; MALE; MESENCHYMAL STROMAL CELLS; NANOPARTICLES; OSTEOBLASTS; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; SKULL FRACTURES; TISSUE SCAFFOLDS;

EID: 84983567870     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.08.023     Document Type: Article

References (57)

1. [1] Dimitriou, R., Jones, E., McGonagle, D., Giannoudis, P.V., Bone regeneration: current concepts and future directions. BMC Med., 9, 2011, 66.
2. [2] Raphel, J., Holodniy, M., Goodman, S.B., Heilshorn, S.C., Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants. Biomaterials 84 (2016), 301–314.
3. [3] Badylak, S.F., Nerem, R.M., Progress in tissue engineering and regenerative medicine. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 3285–3286.
4. [4] Tang, D., Tare, R.S., Yang, L.Y., Williams, D.F., Ou, K.L., Oreffo, R.O.C., Biofabrication of bone tissue: approaches, challenges and translation for bone regeneration. Biomaterials 83 (2016), 363–382.
5. [5] Farokhi, M., Mottaghitalab, F., Shokrgozar, M.A., Ou, K.L., Mao, C., Hosseinkhani, H., Importance of dual delivery systems for bone tissue engineering. J. Control. Release 225 (2016), 152–169.
6. [6] Langer, R., Perspectives and challenges in tissue engineering and regenerative medicine. Adv. Mater. 21 (2009), 3235–3236.
7. [7] Martins, A.M., Alves, C.M., Kasper, F.K., Mikos, A.G., Reis, R.L., Responsive and in situ-forming chitosan scaffolds for bone tissue engineering applications: an overview of the last decade. J. Mater. Chem. 20 (2010), 1638–1645.
8. [8] Ko, I.K., Lee, S.J., Atala, A., Yoo, J.J., In situ tissue regeneration through host stem cell recruitment. Exp. Mol. Med., 45, 2013, e57.
9. [9] Li, Q., Ma, L., Gao, C., Biomaterials for in situ tissue regeneration: development and perspectives. J. Mater. Chem. B 3 (2015), 8921–8938.
10. [10] Mottaghitalab, F., Hosseinkhani, H., Shokrgozar, M.A., Mao, C., Yang, M., Farokhi, M., Silk as a potential candidate for bone tissue engineering. J. Control. Release 215 (2015), 112–128.
11. [11] Melke, J., Midha, S., Ghosh, S., Ito, K., Hofmann, S., Silk fibroin as biomaterial for bone tissue engineering. Acta Biomater. 31 (2016), 1–16.
12. [12] Zhou, H., Lee, J., Nanoscale hydroxyapatite particles for bone tissue engineering. Acta Biomater. 7 (2011), 2769–2781.
13. [13] Liu, H., Xu, G.W., Wang, Y.F., Zhao, H.S., Xiong, S., Wu, Y., et al. Composite scaffolds of nano-hydroxyapatite and silk fibroin enhance mesenchymal stem cell-based bone regeneration via the interleukin 1 alpha autocrine/paracrine signaling loop. Biomaterials 49 (2015), 103–112.
14. [14] Hosogane, N., Huang, Z., Rawlins, B.A., Liu, X., Boachie-Adjei, O., Boskey, A.L., et al. Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells. Int. J. Biochem. Cell. Biol. 42 (2010), 1132–1141.
15. [15] Ji, W., Yang, F., Ma, J., Bouma, M.J., Boerman, O.C., Chen, Z., et al. Incorporation of stromal cell-derived factor-1 alpha in PCL/gelatin electrospun membranes for guided bone regeneration. Biomaterials 34 (2013), 735–745.
16. [16] Kimura, Y., Miyazaki, N., Hayashi, N., Otsuru, S., Tamai, K., Kaneda, Y., et al. Controlled release of bone morphogenetic protein-2 enhances recruitment of osteogenic progenitor cells for de novo generation of bone tissue. Tissue Eng. Part A 16 (2010), 1263–1270.
17. [17] de Guzman, R.C., Saul, J.M., Ellenburg, M.D., Merrill, M.R., Coan, H.B., Smith, T.L., et al. Bone regeneration with BMP-2 delivered from keratose scaffolds. Biomaterials 34 (2013), 1644–1656.
18. [18] Suliman, S., Xing, Z., Wu, X., Xue, Y., Pedersen, T.O., Sun, Y., et al. Release and bioactivity of bone morphogenetic protein-2 are affected by scaffold binding techniques in vitro and in vivo. J. Control. Release 197 (2015), 148–157.
19. [19] Herberg, S., Susin, C., Pelaez, M., Howie, R.N., de Freitas, R.M., Lee, J., et al. Low-dose bone morphogenetic protein-2/stromal cell-derived factor-1β cotherapy induces bone regeneration in critical-size rat calvarial defects. Tissue Eng. Part A 20 (2014), 1444–1453.
20. [20] Lee, C.H., Jin, M.U., Jung, H.M., Lee, J.T., Kwon, T.G., Effect of dual treatment with SDF-1 and BMP-2 on ectopic and orthotopic bone formation. Plos ONE, 10, 2015, e0120051.
21. [21] Hwang, H.D., Lee, J.T., Koh, J.T., Jung, H.M., Lee, H.J., Kwon, T.G., Sequential treatment with SDF-1 and BMP-2 potentiates bone formation in calvarial defects. Tissue Eng. Part A 21 (2015), 2125–2135.
22. [22] Carragee, E.J., Hurwitz, E.L., Weiner, B.K., A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 11 (2011), 471–491.
23. [23] Zara, J.N., Siu, R.K., Zhang, X., Shen, J., Ngo, R., Lee, M., et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A 17 (2011), 1389–1399.
24. [24] Tannoury, C.A., An, H.S., Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 14 (2014), 552–559.
25. [25] Wang, X., Wenk, E., Zhang, X., Meinel, L., Vunjak-Novakovic, G., Kaplan, D.L., Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J. Control. Release 134 (2009), 81–90.
26. [26] Wang, X., Wenk, E., Matsumoto, A., Meinel, L., Li, C., Kaplan, D.L., Silk microspheres for encapsulation and controlled release. J. Control. Release 117 (2007), 360–370.
27. [27] Chen, L., Liu, H.L., Gu, Y., Feng, Y., Yang, H.L., Lumbar interbody fusion with porous biphasic calcium phosphate enhanced by recombinant bone morphogenetic protein-2/silk fibroin sustained-released microsphere: an experimental study on sheep model. J. Mater. Sci. Mater. Med., 26, 2015, 126.
28. [28] Wenk, E., Wandrey, A.J., Merkle, H.P., Meinel, L., Silk fibroin spheres as a platform for controlled drug delivery. J. Control. Release 132 (2008), 26–34.
29. [29] Perez, R.A., Kim, J.H., Buitrago, J.O., Wall, I.B., Kim, H.W., Novel therapeutic core-shell hydrogel scaffolds with sequential delivery of cobalt and bone morphogenetic protein-2 for synergistic bone regeneration. Acta Biomater. 23 (2015), 295–308.
30. [30] Guo, Q., Liu, C., Li, J., Zhu, C., Yang, H., Li, B., Gene expression modulation in TGF-3-mediated rabbit bone marrow stem cells using electrospun scaffolds of various stiffness. J. Cell. Mol. Med. 19 (2015), 1582–1592.
31. [31] Mitropoulos, A.N., Perotto, G., Kim, S., Marelli, B., Kaplan, D.L., Omenetto, F.G., Synthesis of silk fibroin micro-and submicron spheres using a co-flow capillary device. Adv. Mater. 26 (2014), 1105–1110.
32. [32] Luo, Z., Jiang, L., Xu, Y., Li, H., Xu, W., Wu, S., et al. Mechano growth factor (MGF) and transforming growth factor (TGF)-beta 3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model. Biomaterials 52 (2015), 463–475.
33. [33] Liu, Y.S., Ou, M.E., Liu, H., Gu, M., Lv, L.W., Fan, C., et al. The effect of simvastatin on chemotactic capability of SDF-1 alpha and the promotion of bone regeneration. Biomaterials 35 (2014), 4489–4498.
34. [34] Mottaghitalab, F., Farokhi, M., Shokrgozar, M.A., Atyabi, F., Hosseinkhani, H., Silk fibroin nanoparticle as a novel drug delivery system. J. Control. Release 206 (2015), 161–176.
35. [35] Yucel, T., Lovett, M.L., Keplan, D.L., Silk-based biomaterials for sustained drug delivery. J. Control. Release 190 (2014), 381–397.
36. [36] Bessa, P.C., Balmayor, E.R., Azevedo, H.S., Nuernberger, S., Casal, M., van Griensven, M., et al. Silk fibroin microparticles as carriers for delivery of human recombinant BMPs. Physical characterization and drug release. J. Tissue Eng. Regener. Med. 4 (2010), 349–355.
37. [37] Li, A.B., Kluge, J.A., Guziewicz, N.A., Omenetto, F.G., Kaplan, D.L., Silk-based stabilization of biomacromolecules. J. Control. Release 219 (2015), 416–430.
38. [38] Hofmann, S., Foo, C., Rossetti, F., Textor, M., Vunjak-Novakovic, G., Kaplan, D.L., et al. Silk fibroin as an organic polymer for controlled drug delivery. J. Control. Release 111 (2006), 219–227.
39. [39] Huang, X., Brazel, C.S., On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73 (2001), 121–136.
40. [40] Ratanavaraporn, J., Furuya, H., Kohara, H., Tabata, Y., Synergistic effects of the dual release of stromal cell-derived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration. Biomaterials 32 (2011), 2797–2811.
41. [41] Bruderer, M., Richards, R.G., Alini, M., Stoddart, M.J., Role and regulation of Runx2 in osteogenesis. Eur. Cells Mater. 28 (2014), 269–286.
42. [42] Li, S., Tu, Q., Zhang, J., Stein, G., Lian, J., Yang, P.S., et al. Systemically transplanted bone marrow stromal cells contributing to bone tissue regeneration. J. Cell. Physiol. 215 (2008), 204–209.
43. [43] Yu, L.M., Tu, Q.S., Han, Q.Q., Zhang, L., Sui, L., Zheng, L.L., et al. Adiponectin regulates bone marrow mesenchymal stem cell niche through a unique signal transduction pathway: an approach for treating bone disease in diabetes. Stem Cells 33 (2015), 240–252.
44. [44] de Almeida, P.E., van Rappard, J.R.M., Wu, J.C., In vivo bioluminescence for tracking cell fate and function. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H663–H671.
45. [45] Hajjar, R.J., Cormode, D.P., Tracking cell therapy bioluminescence lighting the way. JACC-Cardiovasc. Imag. 5 (2012), 56–58.
46. [46] Granero-Molto, F., Weis, J.A., Miga, M.I., Landis, B., Myers, T.J., O'Rear, L., et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27 (2009), 1887–1898.
47. [47] Huang, S., Xu, L.L., Sun, Y.X., Zhang, Y.F., Li, G., The fate of systemically administrated allogeneic mesenchymal stem cells in mouse femoral fracture healing. Stem Cell Res. Ther., 6, 2015, 206.
48. [48] Sordi, V., Malosio, M.L., Marchesi, F., Mercalli, A., Melzi, R., Giordano, T., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106 (2005), 419–427.
49. [49] Eghbali-Fatourechi, G.Z., Lamsam, J., Fraser, D., Nagel, D., Riggs, B.L., Khosla, S., Circulating osteoblast-lineage cells in humans. N. Engl. J. Med. 352 (2005), 1959–1966.
50. [50] Fan, Y., Ye, J., Shen, F., Zhu, Y., Yeghiazarians, Y., Zhu, W., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow. Metab. 28 (2008), 90–98.
51. [51] Otsuru, S., Tamai, K., Yamazaki, T., Yo shikawa, H., Kaneda, Y., Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 26 (2008), 223–234.
52. [52] Asahara, T., Murohara, T., Sullivan, A., Silver, M., vanderZee, R., Li, T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997), 964–967.
53. [53] Aiuti, A., Webb, I.J., Bleul, C., Springer, T., GutierrezRamos, J.C., The chemokine SDF-1 is a chemoattractant for human CD34(+) hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34(+) progenitors to peripheral blood. J. Exp. Med. 185 (1997), 111–120.
54. [54] Jin, D.K., Shido, K., Kopp, H.G., Petit, I., Shmelkov, S.V., Young, L.M., et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4(+) hemangiocytes. Nat. Med. 12 (2006), 557–567.
55. [55] Li, C.M., Vepari, C., Jin, H.J., Kim, H.J., Kaplan, D.L., Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials 27 (2006), 3115–3124.
56. [56] Zhu, W., Boachie-Adjei, O., Rawlins, B.A., Frenkel, B., Boskey, A.L., Ivashkiv, L.B., et al. A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells. J. Biol. Chem. 282 (2007), 18676–18685.
57. [57] Kanczler, J.M., Oreffo, R.O.C., Osteogenesis and angiogenesis: the potential for engineering bone. Eur. Cells Mater. 15 (2008), 100–114.